Abstract:Necroptosis is a form of regulated necrosis that can be activated by ligands of death receptors and stimuli that induce the expression of death receptor ligands under apoptotic deficient conditions. Activation of necroptosis by ligands of death receptors requires the kinase activity of RIP1, which mediates the activation of RIP3 and MLKL, two critical downstream mediators of necroptosis. Blocking the kinase activity of RIP1, a key druggable target in the necroptosis pathway, by necrostatins inhibits the activation of necroptosis and allows cell survival and proliferation in the presence of death receptor ligands. The activation of necroptosis is modulated by different forms of ubiquitination, including K63, linear and K48 ubiquitination, as well as phosphorylation of RIP1, RIP3 and MLKL. Necroptosis is suppressed by caspase-8/FADD-mediated apoptosis. Deficiency in caspase-8 and FADD leads to embryonic lethality, tissue degeneration and inflammation which can be suppressed by inhibition of RIP1 kinase and RIP3. On the other hand, the lack of RIP3 kinase activity leads to early embryonic lethality which can be suppressed by the loss of caspase-8, suggesting that although the kinase activity of RIP3 is involved in mediating necroptosis, the basal activity of RIP3 kinase may be required for suppressing caspase-8 mediated apoptosis. Necroptosis as well as RIP1- and RIP3-mediated inflammatory response have been implicated in mediating multiple human diseases including TNF-mediated hypothermia and systemic inflammation, ischemic reperfusion injury, neurodegeneration, Gaucher's disease, progressive atherosclerotic lesions, etc. Targeting RIP1 kinase may provide therapeutic benefits for the treatment of human diseases characterized by necrosis and inflammation.

Necroptosis inhibitors: mechanisms of action and therapeutic potential

Necroptosis in Inflammatory Bowel Disease and Other Intestinal Diseases

Molecular Insights into the Mechanism of Necroptosis: The Necrosome as a Potential Therapeutic Target

Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives.

[Research Progress on Receptor Interacting Proteins in Inflammation].

RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development

The Potential Role of Necroptosis in Clinical Diseases (Review)

Necroptosis and its role in infectious diseases

Recent advances in signal pathway of necroptosis and necroptosis targeted therapies

Rip1/Rip3-Regulated Necroptosis As A Target For Multifaceted Disease Therapy (Review)

Protein phosphorylation and kinases: Potential therapeutic targets in necroptosis

Necroptosis in health and diseases

Mitochondrial Mechanisms of Necroptosis in Liver Diseases

Research progress in necroptosis

ZBP1-Mediated Necroptosis: Mechanisms and Therapeutic Implications

Necroptosis: an emerging form of programmed cell death.

Targeting necroptosis: a promising avenue for respiratory disease treatment

Cell type-specific molecular mechanisms and implications of necroptosis in inflammatory respiratory diseases

Necroptosis: Mechanisms and Relevance to Disease.

Initiation and execution mechanisms of necroptosis: an overview

Receptor Interacting Protein Kinases 1/3: The Potential Therapeutic Target for Cardiovascular Inflammatory Diseases